Xvivo Perfusion AB

Xvivo Perfusion AB

0RKL · LSE

206.00SEK+3.60 (+1.78%)

Price History

Full chart

Market Stats

Previous Close202.40
Open202.80
Day Range202.80 – 207.70
52-Week Range160.80 – 314.00
Volume444
Market Cap7.41B
P/E (TTM)9.44
Forward P/E0.00
EPS0.237
Dividend Yield0.00%
Beta1.46
50-Day Avg291.55
200-Day Avg282.98

About

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Company Details

  • CEOMr. Christoffer Rosenblad
  • Employees197
  • HeadquartersGemenskapens gata 9, Mölndal, Sweden, 431 53, UK
  • Websitehttps://www.xvivogroup.com

Leadership

  • Mr. Christoffer RosenbladChief Executive Officer · b. 1975
  • Mr. Kristoffer NordstromCFO and Senior VP of Corporate Strategy & Business Development · b. 1985
  • Ms. Lena Hagman B.Sc.COO & Deputy CEO · b. 1965
  • Ms. Ylva VihojSenior Vice President of Human Resources · b. 1970
  • Dr. Magnus Nilsson Ph.D.Senior Advisor · b. 1956
  • Mr. Johan HolmstromSenior Vice President of Commercial Europe & RoW · b. 1970
  • Mr. Mark ReadeSenior Vice President of North America · b. 1963

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue59.43M68.92M84.70M120.25M138.18M148.34M187.87M220.84M179.86M258.39M415.29M597.54M822.41M812.16M
Growth (%)-+15.98%+22.90%+41.96%+14.91%+7.36%+26.65%+17.55%-18.55%+43.66%+60.73%+43.88%+37.63%-1.25%
Cost of Revenue13.33M14.79M20.66M35.28M48.86M49.48M58.15M68.38M59.79M101.44M132.02M152.43M271.47M278.67M
Gross Profit46.10M54.14M64.05M84.96M89.31M98.86M129.72M152.46M120.07M156.94M283.27M445.11M550.95M533.50M
Gross Margin77.58%78.55%75.61%70.66%64.64%66.64%69.05%69.04%66.76%60.74%68.21%74.49%66.99%65.69%
Operating Expense31.16M43.87M56.16M76.83M81.54M91.67M116.20M141.81M133.95M161.32M264.79M406.61M435.35M440.48M
Operating Income14.94M10.27M7.88M8.13M7.78M7.19M13.52M10.65M-13.88M-4.37M18.48M38.51M115.60M93.02M
Operating Margin25.15%14.90%9.31%6.76%5.63%4.85%7.19%4.82%-7.72%-1.69%4.45%6.44%14.06%11.45%
EBITDA799.00K12.54M8.34M9.75M16.21M22.37M20.25M16.80M-43.33M39.20M39.21M19.03M272.97M153.14M
EBITDA Margin1.34%18.20%9.84%8.11%11.73%15.08%10.78%7.61%-24.09%15.17%9.44%3.19%33.19%18.86%
Net Income9.57M8.05M5.22M5.13M1.50M6.26M12.69M4.94M-43.73M8.15M18.43M91.82M172.18M25.16M
Net Income Margin16.10%11.69%6.16%4.27%1.09%4.22%6.75%2.24%-24.32%3.15%4.44%15.37%20.94%3.10%
R&D8.52M15.19M23.12M31.09M26.32M28.91M47.19M59.72M51.71M30.95M64.68M129.25M112.87M100.69M
R&D as % of Total Revenue14.34%22.05%27.29%25.85%19.05%19.49%25.12%27.04%28.75%11.98%15.58%21.63%13.72%12.40%
Interest Expense-123.00K279.00K100.00K101.00K108.00K128.00K349.00K562.00K276.00K1.09M1.19M5.60M4.60M
Interest Expense % of Total Revenue-0.18%0.33%0.08%0.07%0.07%0.07%0.16%0.31%0.11%0.26%0.20%0.68%0.57%

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets114.52M127.56M199.92M204.18M350.12M538.54M586.61M634.49M1.15B1.54B1.73B2.20B2.40B2.37B
Total Liabilities23.72M25.66M17.91M15.58M33.64M34.21M46.13M56.97M141.85M257.15M302.95M250.57M245.97M260.65M
Total Equity88.77M96.64M178.42M184.87M316.48M504.33M540.48M577.52M1.01B1.29B1.43B1.95B2.16B2.11B
Cash7.78M4.13M48.20M41.23M24.87M195.32M187.06M159.95M354.24M398.70M246.54M546.09M415.52M292.09M
Total Debt9.09M6.66M-----5.55M7.21M5.72M10.01M31.44M34.04M237.89M
Net Debt-7.78M2.53M-48.20M-41.23M-24.87M-195.32M-187.06M-154.40M-347.02M-392.98M-236.54M-514.65M-381.48M-54.20M

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.68M13.46M-4.58M8.58M12.55M22.19M23.63M29.50M-12.27M-12.06M27.86M46.29M111.29M101.07M
Investing Cash Flow-12.26M-14.85M-15.36M-14.29M-29.73M-35.52M-53.20M-83.84M-266.53M-187.70M-197.62M-161.62M-243.81M-258.41M
Financing Cash Flow27.96M-2.30M63.54M-1.47M244.00K184.80M19.20M25.55M482.77M234.61M-6.84M418.55M-10.90M72.25M
Capital Expenditure708.00K383.00K383.00K7.11M20.51M34.93M54.71M83.69M64.68M94.07M130.95M43.02M70.73M93.72M
Free Cash Flow5.97M13.08M-4.97M1.47M-7.96M-12.74M-31.08M-54.19M-76.94M-106.13M-103.09M3.27M40.56M7.34M
FCF to OCF89.39%97.16%108.36%17.09%-63.44%-57.43%-131.54%-183.66%627.29%880.11%-370.08%7.07%36.44%7.27%

Earnings

Report DateDec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Jan 25, 2024Apr 24, 2024Jul 12, 2024Oct 24, 2024Jan 28, 2025Apr 24, 2025Jul 11, 2025Oct 23, 2025Jan 27, 2026Apr 24, 2026Jul 14, 2026Oct 22, 2026
EPS Estimate----------------------------------0.632.06-12.651.340.860.84
EPS Actual-0.02-0.000.04-0.010.210.150.150.000.18-0.010.080.18-0.070.25-0.60-0.51-0.680.20-0.31-0.040.410.160.260.180.020.480.230.082.170.720.862.711.15-0.390.050.141.001.150.52-
Surprise-----------------------------------92.10%-93.33%107.93%-14.16%-39.94%-
Timing----------------------------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap7.41B
Enterprise Value6.75B
Trailing P/E9.44
Forward P/E0.00
Price / Sales9.13
Price / Book0.00
EPS0.237
Book Value69.85
Revenue (TTM)895.23M
Gross Profit (TTM)647.00M
EBITDA158.26M
Profit Margin9.89%
Operating Margin10.46%
Return on Equity4.13%
Return on Assets2.99%
Shares Outstanding26.40M
Shares Float25.13M
Beta1.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%